http://wl28www163.webland.ch en Fri, 03 Sep 2010 12:22:36 +0200 Biotech in the New EU Member States: Policy Recommendations The study carried-out on the development status and capacity of healthcare biotechnology in the new EU Member States and candidate countries shows a much contrasted picture of biotechnology development in this region. Each country has a different economic development strategy and a unique history and capacity in the life-science and healthcare sector which determines its path to development. Based on these observations, it would be unsuitable to propose general recommendations in a sort of unique formula to build or develop a healthy healthcare biotechnology sector. Donwnload free 14 pages report at our Download Section. http://wl28www163.webland.ch/index.php?id=196608 196608 Mon, 28 Sep 2009 00:00:00 +0200 The Food and Drug Administration approved Arzerra, a leukemia treatment that will be marketed by GlaxoSmithKline PLC for patients who have failed to respond to other therapies.Arzerra was developed by U.K.-based Glaxo and Danish company Genmab A/S. http://wl28www163.webland.ch/index.php?id=196443 196443 Wed, 28 Oct 2009 00:00:00 +0100 The international regulatory affairs network - regulanet® - currently mainly operating in Europe is increasingly active globally. http://wl28www163.webland.ch/index.php?id=191010 191010 Mon, 26 Oct 2009 00:00:00 +0100 One of the first institutional network partners is the swiss national biotech industry association - Swiss Biotech Association. http://wl28www163.webland.ch/index.php?id=191357 191357 Fri, 23 Oct 2009 00:00:00 +0200 Biotech in the New EU Member States: an Emerging Sector This report is the first of its kind to try and understand the state of the biotechnology industry in the new Member States and candidate countries. As with any bottom-up work, it took a lot of effort and persistence to gather data on current and prospective developments in this area. Our goal was to strengthen the understanding of the European biotechnology scene and we believe that with the knowledge accumulated we have reached this goal. This report should enable policy makers and investors to make informed decisions about biotechnology support and development. The databases developed during this project will also provide better international visibility to the companies, which could lead to new cooperation or investment. Donwnload free 33 pages report at our Download Section. http://wl28www163.webland.ch/index.php?id=196622 196622 Mon, 28 Sep 2009 00:00:00 +0200 0 http://wl28www163.webland.ch/index.php?id=272362 272362 Thu, 01 Jan 1970 01:00:00 +0100 Research and Markets (http://www.researchandmarkets.com/research/1df868/japanese_pharmaceu) has announced the addition of the "Japanese Pharmaceutical Sector: Industry Profile" report to their offering. http://wl28www163.webland.ch/index.php?id=324729 324729 Thu, 08 Jul 2010 00:00:00 +0200 Positron Corporation (OTCBB:POSC). The growth rate among nonradiologists who own or lease PET equipment was far higher than radiologists between 2002 and 2007, according to a study published in the March issue of the Journal of the American College of Radiology (JACR Volume 7, Issue 3, March 2010, Pages 187-191). http://wl28www163.webland.ch/index.php?id=288882 288882 Tue, 09 Mar 2010 00:00:00 +0100 Venn Life Sciences would like to announce the appointment of Dale Trask as Vice President Global Business Development, marking an important phase in the company's growth. Mr. Trask brings extensive experience in Clinical Research Organisation (CRO) business development and will be responsible for enhancing Venn's business partnerships, strategic relationships and growth into new markets. http://wl28www163.webland.ch/index.php?id=288854 288854 Tue, 09 Mar 2010 00:00:00 +0100 Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has received from the Food and Drug Administration (FDA) an Investigational Device Exemption (IDE) approval to initiate a pivotal Phase III clinical trial upon obtaining institutional review board (IRB) approval from the clinical sites, using the Company's Microfocus APA 1000 System for the treatment of breast cancer. Medifocus had already announced on June 9, 2009 that Health Canada had granted full Investigational Testing Authorization (ITA) approval to allow the initiation of the same pivotal Phase III study in Canada. http://wl28www163.webland.ch/index.php?id=288861 288861 Tue, 09 Mar 2010 00:00:00 +0100 It's long been known that obesity is linked to increased risk of developing colon cancer, but now researchers at the Mayo Clinic campus in Minnesota have found that obesity is associated with worse outcomes in patients who have already been diagnosed and treated for the cancer. http://wl28www163.webland.ch/index.php?id=288868 288868 Tue, 09 Mar 2010 00:00:00 +0100 HealthHelp, a leading specialty benefit management provider, continues to target health care cost drivers by adding diagnostic cardiac catheterization to its well-established and effective suite of services. http://wl28www163.webland.ch/index.php?id=288875 288875 Tue, 09 Mar 2010 00:00:00 +0100